Phibro Animal Health (PAHC) AI Stock Analysis

• Market Cap: $1.51B
• Dividend Yield: 1.29%
• Average Volume (3M): 304.30K
• Price to Earnings (P/E): 22.4
• Beta (1Y): 1.07
• Revenue Growth: 33.71%
• EPS Growth: 289.48%
• Country: US
• Employees: 1,940
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.73
• Shares Outstanding: 20,447,575
• 10 Day Avg. Volume: 317,084
• 30 Day Avg. Volume: 304,301
• PEG Ratio: 0.01
• Price to Book (P/B): 3.62
• Price to Sales (P/S): 0.80
• P/FCF Ratio: 24.73
• Enterprise Value/Market Cap: 1.56
• Enterprise Value/Revenue: 1.68
• Enterprise Value/Gross Profit: 5.40
• Enterprise Value/Ebitda: 12.77
• 1Y Price Target: $47.50
• Price Target Upside: 27.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 2.74
• Revenue Forecast (FY): $1.46B

• Rating: 64 Neutral
• Price Target: $40.00 ▲(7.38% Upside)

Phibro Animal Health's strong earnings call performance and increased guidance are the most significant factors driving the score. However, financial risks from high leverage and negative cash flow growth, along with bearish technical indicators, moderate the overall score.

Positive Factors

Animal Health Segment Growth

The robust growth in the Animal Health segment, driven by Medicated Feed Additives, strengthens Phibro's core business and market position.

New Product Launch

The launch of Restoris enhances Phibro's product portfolio, supporting its strategic focus on innovation and expanding its companion animal market.

Leadership Succession Plan

The generational CEO succession plan ensures leadership continuity and supports Phibro's long-term growth strategy and competitive position.

Negative Factors

High Leverage

High leverage can pose financial risks, potentially limiting Phibro's ability to invest in growth opportunities and affecting financial stability.

Negative Free Cash Flow Growth

Negative free cash flow growth highlights potential cash flow challenges, which can impact Phibro's ability to fund operations and strategic initiatives.

Flat Revenue Guidance

Despite strong Q1 results, unchanged revenue guidance suggests caution or potential headwinds, impacting long-term revenue growth expectations.

Phibro Animal Health Business Overview & Revenue Model

Company Description

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.

How the Company Makes Money

Phibro Animal Health generates revenue through the sale of its products across its three business segments. The Animal Health segment, which includes vaccines and pharmaceuticals, constitutes a significant portion of its earnings, driven by demand for improved animal care and disease prevention. The Mineral Nutrition segment provides essential minerals and nutritional products that are crucial for animal growth and productivity. The Performance Products segment contributes to revenue through specialty products used in various industries. Phibro also benefits from strategic partnerships with distributors and other companies in the agricultural sector, enhancing its market reach and sales effectiveness. Additionally, the company invests in research and development to innovate and expand its product offerings, further supporting its revenue generation efforts.

Phibro Animal Health Financial Statement Overview

Summary

Phibro Animal Health demonstrates strong revenue growth and profitability, with efficient operations reflected in EBIT and EBITDA margins. However, high leverage and negative free cash flow growth present potential risks. The company should focus on improving cash flow management and reducing debt levels to enhance financial stability.

Income Statement

Phibro Animal Health shows a solid revenue growth rate of 7.98% TTM, indicating strong market demand. The gross profit margin of 31.17% and net profit margin of 4.85% TTM reflect stable profitability, though there is room for improvement in net margins. EBIT and EBITDA margins are healthy at 6.08% and 12.35% TTM, respectively, suggesting efficient operations.

Balance Sheet

The company's debt-to-equity ratio of 1.96 TTM indicates high leverage, which could pose financial risks. However, a return on equity of 24.43% TTM shows effective use of equity to generate profits. The equity ratio of 22.49% TTM suggests moderate financial stability.

Cash Flow

Free cash flow growth is negative at -18.03% TTM, highlighting potential cash flow challenges. The operating cash flow to net income ratio of 0.28 TTM and free cash flow to net income ratio of 0.45 TTM indicate moderate cash generation relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.40B	1.30B	1.02B	977.89M	942.26M	833.35M
Gross Profit	436.23M	399.94M	313.09M	298.24M	285.40M	271.38M
EBITDA	184.25M	146.85M	69.06M	106.03M	117.13M	110.21M
Net Income	67.82M	48.26M	2.42M	32.61M	49.17M	54.38M
Balance Sheet
Total Assets	1.39B	1.36B	982.18M	971.40M	931.70M	841.33M
Cash, Cash Equivalents and Short-Term Investments	85.27M	77.04M	114.61M	81.28M	91.25M	93.21M
Total Debt	785.10M	761.55M	525.46M	509.97M	470.48M	426.71M
Total Liabilities	1.07B	1.08B	725.54M	688.89M	669.26M	602.80M
Stockholders Equity	311.68M	285.68M	256.64M	282.51M	262.44M	238.53M
Cash Flow
Free Cash Flow	34.29M	41.83M	46.36M	-38.48M	-5.39M	18.99M
Operating Cash Flow	76.80M	80.12M	87.59M	13.31M	31.65M	48.31M
Investing Cash Flow	-306.77M	-288.69M	-48.19M	-74.02M	-22.58M	-18.58M
Financing Cash Flow	252.67M	207.13M	-6.77M	26.99M	16.34M	-17.00M

Phibro Animal Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 37.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAHC, the sentiment is Negative. The current price of 37.25 is below the 20-day moving average (MA) of 40.75, below the 50-day MA of 41.28, and above the 200-day MA of 30.71, indicating a neutral trend. The MACD of -0.66 indicates Positive momentum. The RSI at 36.36 is Neutral, neither overbought nor oversold. The STOCH value of 51.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAHC.

Phibro Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZTS	74 Outperform	$53.87B	20.60	49.87%	1.69%	2.68%	11.51%
ELAN	69 Neutral	$11.08B	305.90	0.54%	―	3.08%	-82.39%
PAHC	64 Neutral	$1.51B	22.40	23.79%	1.29%	33.71%	289.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Phibro Animal Health Corporate Events

Phibro Animal Health Announces Generational CEO Succession Plan

On December 18, 2025, Phibro Animal Health announced a planned leadership transition effective July 1, 2026, under which long-time Chairman, Chief Executive Officer and President Jack Bendheim will move into the role of Executive Chairman while continuing as Chairman of the Board, and Daniel (Dani) Bendheim will be appointed Chief Executive Officer and President. The move formalizes a generational succession after Jack Bendheim’s decades-long tenure, during which he led significant global expansion and portfolio growth, and maintains continuity as the full executive leadership team remains in place with unanimous board support; Dani Bendheim’s promotion, backed by his extensive operational and strategic experience and involvement in the company’s transformation initiatives, is intended to support Phibro’s long-term growth strategy and reinforce its competitive position in the animal health industry.

Phibro Animal Health Reports Strong Q1 Sales Growth

On November 4, 2025, Phibro Animal Health Corporation held its annual stockholders meeting, where key decisions were made including the election of directors and approval of executive compensation. The company reported a strong start to fiscal 2026 with a 40% increase in net sales for the first quarter, driven by significant growth in its Animal Health segment. Phibro’s strategic initiatives and market demand have led to increased earnings guidance, highlighting its competitive positioning and commitment to long-term value creation.

Phibro Animal Health Declares Quarterly Cash Dividend

On November 4, 2025, Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock, payable on December 17, 2025, to stockholders recorded by November 26, 2025. This announcement reflects Phibro’s continued commitment to returning value to its shareholders and may positively impact its market positioning by reinforcing investor confidence.